-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-11-05
Values as of: 2024-11-05
The investment seeks total return, with an emphasis on income as the source of that total return. The fund seeks to achieve its investment objective by investing in a global portfolio of fixed income securities of various maturities, ratings and currency denominations. The adviser intends to utilize various investment strategies in a broad array of fixed income sectors. The fund may purchase fixed income securities issued by U.S. or foreign corporations or financial institutions, including debt securities of all types and maturities, convertible securities and preferred stocks. It is non-diversified.
Company Website : www.alpsfunds.com
Currency: USD
Country : USA
Inception Date: 30/12/2014
Primary Benchmark: Poliwogg Medical Breakthroughs TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.5%
Management Expense Ratio: 0.50 %
N/A
N/A
| Symbol | Company Name | Allocation |
|---|---|---|
| CORT | Corcept Therapeutics Incorporated | 4.07 % |
| ALKS | Alkermes Plc | 3.78 % |
| KRYS | Krystal Biotech Inc | 3.59 % |
| CRNX | Crinetics Pharmaceuticals Inc | 3.20 % |
| ACLX | Arcellx Inc | 3.08 % |
| IMVT | Immunovant Inc | 2.89 % |
| RNA | Avidity Biosciences Inc | 2.73 % |
| PTCT | PTC Therapeutics Inc | 2.63 % |
| VRNA | Verona Pharma PLC ADR | 2.58 % |
| DNLI | Denali Therapeutics Inc | 2.28 % |
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR.. | 0.13 % |
N/A |
USD 36.67B |
| FHLC | Fidelity® MSCI Health Care In.. | 0.08 % |
N/A |
USD 2.62B |
| FXH | First Trust Health Care AlphaD.. | 0.63 % |
N/A |
USD 1.09B |
| XHE | SPDR® S&P Health Care Equipme.. | 0.35 % |
N/A |
USD 0.23B |
| IDNA | iShares Genomics Immunology an.. | 0.00 % |
N/A |
USD 0.12B |
| XHS | SPDR® S&P Health Care Service.. | 0.35 % |
N/A |
USD 0.07B |
| HTEC | Robo Global® Healthcare Techn.. | 0.00 % |
N/A |
USD 0.05B |
| BBP | Virtus LifeSci Biotech Product.. | 0.79 % |
N/A |
USD 0.02B |
| BBC | Virtus LifeSci Biotech Clinica.. | 0.79 % |
N/A |
USD 0.01B |
| IHE | iShares U.S. Pharmaceuticals E.. | 0.42 % |
N/A |
N/A |
N/A
| Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 19.52% | 95% | A | 76% | C+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 19.52% | 95% | A | 76% | C+ | ||
| Trailing 12 Months | |||||||
| Capital Gain | 53.50% | 95% | A | 86% | B+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 53.50% | 95% | A | 87% | B+ | ||
| Trailing 5 Years | |||||||
| Capital Gain | 11.00% | 57% | F | 59% | D- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 11.00% | 57% | F | 59% | D- | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -0.21% | 19% | F | 32% | F | ||
| Dividend Return | -0.17% | 19% | F | 22% | F | ||
| Total Return | 0.04% | 16% | F | 2% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 27.43% | 29% | F | 38% | F | ||
| Risk Adjusted Return | -0.60% | 19% | F | 22% | F | ||
| Market Capitalization | 0.12B | 50% | F | 30% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
